The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi
Phase 2
Withdrawn
- Conditions
- Parathyroid AdenomaCancer - Bone
- Registration Number
- ACTRN12605000153617
- Lead Sponsor
- Robert Williams
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Previous negative 99mTc Sestamibi parathyroid scan. No subsequent parathyroid surgery. Abnormal parathyroid Hormone (PTH ) levels. Strong clinical suspicion of parathyroid adenoma. Permission of referring doctor. Informed consent of patient.
Exclusion Criteria
Age younger than 18 years, pregnancy, unable to gain informed consent, unstable cardiac disease, Asthma, hypotension, hypersensitivity to aspirin or dipyridamole.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method